Skip to main content
Premium Trial:

Request an Annual Quote

MDS Revenues Surge on Mass Spec Sales

NEW YORK, Sept. 9 (GenomeWeb News) - Buoyed by sales of its 4000 series of mass spec instruments, Toronto-based MDS today reported a 5 percent growth in earnings for its third quarter ending July 31.


The company, which is undergoing a strategic reorganization, had revenues of CA$465 million, up from CA$444 million for the year-ago quarter as sales for the company's API 4000 and 4000 Qtrap mass spec instruments increased 36 percent, the company said. Net income was CA$50 million, compared to CA$33 million for the same quarter in 2003.


MDS has net revenues of and finished the quarter with CA$273 million in cash and cash equivalents. The company reported a loss of CA$7 million on research and development, compared to CA$11 million in Q3 '03.


On Sept. 1, MDS and Applied Biosystems announced an expansion of their mass spectrometry joint venture (click here to read the article).


The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more